Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Generally speaking
Careplus nta is the lowest in 7 gloves (0.34)
Revenue on QoQ only increase 3.2% is because of lack of asset to generate more sales or demand market already fully fulfill ?
Of course , the latest quarter report page 19 at the prospect , 4 more production line for end of 2020, but we aspect the next qr first (October to December) , in case of USA department of labour blacklist Malaysia glove and vaccine of USA and China release soon , will careplus still going better ?
Just for discussion TQ
Look at the number of cases increasing everyday worldwide, it has just break new high, ASP of glove will continue to remain high at least until next year 2nd quarter, even if the vaccine is out today, as long as the ASP is there, glove counter will keep climbing, it takes time for glove counter to go down, maybe 1 or 2 years later
I believe everyone knows that the revenue for glove counter will increase for the next few quarters or even years. But the price of glove counter is another story. Maybe the valuation of the glove counter has reached its peak. Just my 2 cents
For the next few QR's, with new lands acquired, new factories built, new machines installed, NTA and revenue will keep increasing. But I can't determine if PE will be on the rise or otherwise. Depends on how glove sector reacts to vaccine availability I guess?
Careplus JV partner Ansell has relatively big presence in Oz, Europe. Ansell has seen market expansion into China, India, Latin America and CEE. This is what you call strategic partner and hidden gem with well diversified base.
On its own, Brazil, Vietnam,US, EU....all in, has distribution across 11 countries. Well diversified, strategically partnered, and operationally secured.
